[1] OGURTSOVA K, da ROCHA FERNANDES J D, HUANG Y, et al. IDF Diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017(128):40-50. [2] WANG L M, GAO P, ZHANG M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in china in 2013[J]. JAMA,2017,317(24):2515-2523. [3] WANGQING C, KEXIN S, RONGSHOU Z, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12. [4] 王蕾,吴益康,马骏,等. 2型糖尿病患者的恶性肿瘤发病风险:基于浙江省嘉兴市糖尿病管理数据的回顾性队列研究[J]. 肿瘤,2019,39(07):548-557. [5] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2018, 68(6):394-424. [6] 王莹莹,马骁,杨万水,等. 2型糖尿病与消化系统恶性肿瘤队列研究的Meta分析[J]. 中国肿瘤,2013,22(11):845-857. [7] KANG J H, LEE S I, LIM D H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase iii trial comparing chemotherapy plus best supportive care with best supportive care alone[J]. J Clin Oncol, 2012, 30(13):1513-1518. [8] THUSS-PATIENCE P C, KRETZSCHMAR A, BICHEY D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III stuhe dy of the arbeitsgemeinschaft internistisconkologie (AIO)[J]. Eur J Cancer, 2011, 47(15):2306-2314. [9] FORD H E R, MARSHALL A, BRUDGEWATER J A, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial[J]. Lancet Oncol, 2014, 15(1):78-86. [10] BEN Q, XU M, NING X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies[J]. Eur J Cancer, 2011, 47(13):1931-1937. [11] SHIMOYAMA S. Diabetes mellitus carries a risk of gastric cancer: A meta-analysis[J]. World J Gastroenterol, 2013, 19(40):6902-6910. [12] de BRUIJN K M J, ARENDS L R, HANSEN B E, et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer[J]. Br J Surg, 2013, 100(11):1421-1429. [13] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):359-386. [14] 秦娟,吴艳,朱晓荣,等. 2型糖尿病并发恶性肿瘤风险的Logistic回归分析[J]. 肿瘤预防与治疗,2017,30(6):433-436,452. [15] 揭育丽,梁伟娟. 血清CA19-9对胰腺癌及胆道疾病临床诊断的价值[J]. 中国热带医学,2009,9(5):871-872. [16] 郁肖夫,郑晓. 糖类抗原CA125 CA199 CA724癌胚抗原对大肠癌的诊断价值[J]. 中国药物与临床,2019,19(3):395-397. [17] 谢晓英,钟日辉,刘晓强,等. 糖尿病患者血清肿瘤标志物水平及其与并发症的关系[J]. 中国卫生检验杂志,2015,25(7):1005-1007. [18] 代伟伟,刘正新,徐宝宏. 肝硬化和肝癌患者血清CA125、CA199、AFP和CEA水平变化[J]. 实用肝脏病杂志,2017,20(1):81-84. [19] 秦娟,吴艳,朱晓荣,等. 2型糖尿病合并恶性肿瘤患者代谢相关因素与肿瘤临床特征的相关性分析[J]. 肿瘤预防与治疗,2018,31(2):99-102. [20] STEPHANIE C,HARDY R W. The metabolic syndrome: a high-risk state for cancer? [J]. Am J Pathol,2006,169(5): 1505-1522. [21] 陈丹,张伟斌,吴敏华. 老年2型糖尿病血糖波动性及其与血清肿瘤标志物水平及结直肠癌的关系分析[J]. 广东医学,2017,38(21):3299-3301. [22] 陶然,周金意,苏健,等. 江苏省成年人血脂异常与糖尿病关系[J]. 中国公共卫生,2015,31(5):558-562. [23] WANG C, WANG X, GONG G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies [J]. Int J Cancer, 2012, 130(7):1639-1648. [24] 董大庆,李炳庆,何培元. 血脂在结直肠癌中应用价值的研究[J]. 世界最新医学信息文摘,2019,19(6):199-201. |